AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04017221
Drug: Other treatment combinations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
Trial: NCT00675181
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg per os
Trial: NCT00675181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os
Trial: NCT03166228
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline as distension medium as long as diathermy is not in use
Trial: NCT01137708
Drug: ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
Trial: NCT01137708
Drug: CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
Trial: NCT03166228
Drug: 1.5% Glycine only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% Glycine alone during hysteroscopy as long as diathermy is in use
Trial: NCT03838666
Drug: Suspension of human autologous MSC 3P
RxNorm normalized name: microspheres of human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
Trial: NCT01205646
Drug: zoledronate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
Trial: NCT00823472
Drug: Mild stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
Trial: NCT02534376
Drug: ezetimibe 10mg-simvastatin 40mg
RxNorm normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
Trial: NCT02515305
Drug: Placebo gel (combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00997490
Drug: Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 2 tablets/day over 6 weeks
Trial: NCT02099240
Drug: oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
Trial: NCT01646736
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 1.0 intravenous every month.
Trial: NCT04233801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00495885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, one tablet taken around bedtime
Trial: NCT01996605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered spinally
Trial: NCT02198469
Drug: Er:YAG AFL-PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
Trial: NCT02198469
Drug: MAL-PDT
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Trial: NCT02402049
Drug: Lachesis 30C
RxNorm normalized name: Lachesis muta venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
Trial: NCT02402049
Drug: Sepia 30C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
Trial: NCT02402049
Drug: Placebo Sepia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
Trial: NCT02402049
Drug: Placebo Nux vomica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
Trial: NCT02402049
Drug: Placebo pulsatilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
Trial: NCT02402049
Drug: Placebo Folliculinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
Trial: NCT04397510
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Heparin
Trial: NCT01371799
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01371799
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg and 8mg Study drug
Trial: NCT02417935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02469597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
Trial: NCT00840177
Drug: pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,280 mg/day given orally on days 1-8
Trial: NCT02898792
Drug: Targeted infusion of remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
Trial: NCT01154985
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x Placebo capsules three times a day (TID) for 365 days
Trial: NCT03633396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once a month
Trial: NCT01557153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
Trial: NCT00542139
Drug: Bupivocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular injection of 10ml of Bupivocaine
Trial: NCT00537810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily
Trial: NCT02853318
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00517634
Drug: SFC
RxNorm normalized name: SFC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
Trial: NCT00517634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01156012
Drug: T2345
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of T2345
Trial: NCT01156012
Drug: Prostaglandin
RxNorm normalized name: Prostaglandin
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop
Trial: NCT00027404
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03345901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally BID - twice daily
Trial: NCT02993133
Drug: Cellcept® in autoimmune bullous dermatoses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
Trial: NCT01026545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match 500 mg dose once daily for 10 days
Trial: NCT01026545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match 750 mg dose once daily for 10 days
Trial: NCT01026545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match 1100 mg dose once daily for 10 days
Trial: NCT01026545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional cohort to match dose not greater than 1100 mg
Trial: NCT04104399
Drug: XC101-D13H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
Trial: NCT04104399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied as matching capsules
Trial: NCT02583399
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen, 10 mg/kg
Trial: NCT00003389
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given IV
Trial: NCT03000595
Drug: SAN007 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cream containing 5% East Indian sandalwood oil (EISO).
Trial: NCT03000595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle cream
Trial: NCT00003389
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given IV
Trial: NCT01116661
Drug: 5-Aminolevuline Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
Trial: NCT00722046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 60 days (10 doses total)
Trial: NCT03478540
Drug: Anti-Retroviral Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
Trial: NCT01092572
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg per day orally for 12 weeks.
Trial: NCT01092572
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 tablet once daily for 12 weeks
Trial: NCT03112681
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
Trial: NCT01594749
Drug: Rescue Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03812198
Drug: LEO 32731 modified release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
Trial: NCT03010917
Drug: Fish Oil with ethanol and placebo ethanol infusions
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fish Oil with ethanol and placebo ethanol infusions
Trial: NCT03010917
Drug: Placebo with ethanol and placebo ethanol infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with ethanol and placebo ethanol infusions
Trial: NCT00387881
Drug: sumatriptan succinate / naproxen sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan 85mg / naproxen sodium 500mg
Trial: NCT00387881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Treximet tablets
Trial: NCT05621330
Drug: QL0911
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Trial: NCT03812198
Drug: LEO 32731 blend, hard capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Trial: NCT03812198
Drug: LEO 32731 API, hard capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Trial: NCT03812198
Drug: LEO 32731 gastro-resistant capsule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
Trial: NCT03812198
Drug: LEO 32731
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
Trial: NCT05621330
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Trial: NCT00659412
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT00659412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular
Trial: NCT05048914
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: treatment of acute migraine attack
Trial: NCT03658408
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg sugar pill given orally 4 times a day
Trial: NCT03990649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat matching placebo tablets
Trial: NCT03793010
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Intra-articular injection
Trial: NCT00003994
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00908050
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01444469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder
Trial: NCT04366089
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Trial: NCT00003684
Drug: theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01989936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Trial: NCT03356769
Drug: AED
RxNorm normalized name: Zaedoc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintain the dosages and the drugs throughout the 3-month observation time
Trial: NCT00714714
Drug: Tretinoin Gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.1% topically applied daily in a split face model for two weeks
Trial: NCT01131780
Drug: Ibuprofen + Pseudoephedrine Hydrochloride
RxNorm normalized name: ibuprofen / pseudoephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Trial: NCT01199640
Drug: MLN1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
Trial: NCT00172003
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01841086
Drug: Anplag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Trial: NCT03356769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 5mg/Kg/d, once every day, 25mg per tablets
Trial: NCT01058395
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
Trial: NCT02714400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One piece of placebo before sleep
Trial: NCT00656357
Drug: SYN117 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00656357
Drug: SYN117 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN117 80 mg
Trial: NCT00656357
Drug: SYN117 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN117 160 mg
Trial: NCT01179724
Drug: high dose proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
Trial: NCT00003343
Drug: endocrine-modulating drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02219516
Drug: RDEA3170
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00420823
Drug: Taurine 4g
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00223067
Drug: TAIZ
RxNorm normalized name: ALCOHOL 400 mL in 500 mL TOPICAL LIQUID [Miracle Power Hand Sanitaizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03259516
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
Trial: NCT00700986
Drug: AZD9056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, 800mg, one single administration
Trial: NCT02319564
Drug: Beclomethasone and Salbutamol
RxNorm normalized name: salbutamol and beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02319564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00700986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT04559126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match EDP-297